AcuCort receives a second US patent protection for its drug ISICORT®
AcuCort AB (Spotlight Stock Market: ACUC) today announces that the US Patent and Trademark Office, USPTO, has announced that the company’s patent application in the US for dexamethasone oral film is granted. This is the second patent protection in the US for AcuCort’s drug ISICORT®. This strengthened patent protection and extended exclusivity on the US market is in line with company’s strategy.
ISICORT® is a thin, fast-dissolving and user-friendly oral film for the treatment of acute and severe allergic reactions, for croup in children and chemotherapy-induced nausea and vomiting (CINV). The fast-dissolving oral film contains the glucocorticoid dexamethasone which is a well-known, often used and well-documented anti-inflammatory substance.
”I am very pleased that we have received a second granted patent protection in the US for ISICORT®. The positive decision from the US Patent and Trademark Office means that AcuCort now has two active patents that protect our drug ISICORT® in the US, which is one of the largest and most important markets in the world,” says Jonas Jönmark, CEO of AcuCort AB.
The information was submitted for publication, through the agency of the contact person below, on September 3, 2021.
For more information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
Email: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). A national application was approved by the Swedish Medical Products Agency (MPA) in October 2020. In February 2021, ISICORT® was granted an additional indication – the treatment of COVID-19 patients who need supplemental oxygen treatment. Altogether, this strengthens the company’s assessment that the time to commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.com.
Tags: